Gastrointestinal regulatory peptides and their receptors

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 21, Issue 1, 2014, Pages 1-2

  Weber, H Christian ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; GASTROINTESTINAL POLYPEPTIDE; PROTON PUMP INHIBITOR;

ACHLORHYDRIA; CLINICAL PRACTICE; DIET; EDITORIAL; ENTEROENDOCRINE CELL; FATTY LIVER; GASTROINTESTINAL TUMOR; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MICROBIOME; NEUROENDOCRINE TUMOR; OBESITY; PATHOPHYSIOLOGY; STOMACH ACID SECRETION;

BONE DENSITY; FEMALE; GASTRIC INHIBITORY POLYPEPTIDE; GASTROINTESTINAL HORMONES; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MICROBIOTA; PROTON PUMP INHIBITORS; SIGNAL TRANSDUCTION;

EID: 84892367990     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/MED.0000000000000035     Document Type: Editorial

References (20)

1. Woods SC. The control of food intake: Behavioral versus molecular perspectives. Cell Metab 2009; 9: 489-498
2. Weber HC. Editorial overview: Gastrointestinal regulatory peptides. CurrOpin Endocrinol Diabetes Obes 2010; 17: 31-32
3. Engelstoft MS, Egerod KL, Holst B, Schwartz TW. A gut feeling for obesity: 7TM sensors on enteroendocrine cells. Cell Metab 2008; 8: 447-449
4. Abraham NS. Proton pump inhibitors: Potential adverse effects. Curr Opin Gastroenterol 2012; 28: 615-620
5. Heidelbaugh JJ, Kim AH, Chang R, Walker PC. Overutilization of proton-pump inhibitors: What the clinician needs to know. Therap Adv Gastroenterol 2012; 5: 219-232; Epub 2012/07/11. doi: 10.1177/1756283X12437358
6. Kwok CS, Yeong JK, Loke YK. Meta-Analysis: Risk of fractures with acidsuppressing medication. Bone 2011; 48: 768-776
7. Moayyedi P, Leontiadis GI. The risks of PPI therapy. Nat Rev Gastroenterol Hepatol 2012; 9: 132-139
8. Trikudanathan G, Israel J, Cappa J, O'Sullivan DM. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients: A systematic review and meta-Analysis. Int J Clin Pract 2011; 65: 674-678
9. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-2056
10. Bajaj JS, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. Aliment Pharmacol Therap 2012; 36: 866-874
11. Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 170: 772-778
12. Reimer C. Safety of long-Term PPI therapy. Best Pract Res Clin Gastroenterol 2013; 27: 443-454
13. Klimstra DS. Pathology reporting of neuroendocrine tumors: Essential elements for accurate diagnosis, classification, and staging. Semin Oncol 2013; 40: 23-36
14. Modlin IM, Drozdov I, Kidd M. The identification of gut neuroendocrine tumor disease by multiple synchronous transcript analysis in blood. PLoS One 2013; 8: E63364
15. Human Microbiome Project Consortium. A framework for human microbiome research. Nature 2012; 486: 215-221
16. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 2012; 486: 207-214
17. Chatterjee B, Thakur SS. Microbial profiling: Extend ethnicity of human microbiome. Nature 2012; 487: 39
18. Schloissnig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome. Nature 2013; 493: 45-50
19. WuGD, Lewis JD. Analysis of the human gut microbiome and association with disease. Clin Gastroenterol Hepatol 2013; 11: 774-777
20. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: A Rome foundation report. Gut 2013; 62: 159-176